| TLR10 is a negative regulator of both MyD88-dependent and-independent TLR signaling S Jiang, X Li, NJ Hess, Y Guan, RI Tapping The Journal of Immunology 196 (9), 3834-3841, 2016 | 155 | 2016 |
| TLR10 is a B cell intrinsic suppressor of adaptive immune responses NJ Hess, S Jiang, X Li, Y Guan, RI Tapping The Journal of Immunology 198 (2), 699-707, 2017 | 52 | 2017 |
| TLR10 suppresses the activation and differentiation of monocytes with effects on DC-mediated adaptive immune responses NJ Hess, C Felicelli, J Grage, RI Tapping Journal of Leucocyte Biology 101 (5), 1245-1252, 2017 | 51 | 2017 |
| GVHD pathogenesis, prevention and treatment: lessons from humanized mouse transplant models NJ Hess, ME Brown, CM Capitini Frontiers in immunology 12, 723544, 2021 | 40 | 2021 |
| Different human immune lineage compositions are generated in non-conditioned NBSGW mice depending on HSPC source NJ Hess, PN Lindner, J Vazquez, S Grindel, AW Hudson, AK Stanic, ... Frontiers in Immunology 11, 573406, 2020 | 31 | 2020 |
| Early T cell activation metrics predict graft-versus-host disease in a humanized mouse model of hematopoietic stem cell transplantation NJ Hess, AW Hudson, P Hematti, JE Gumperz The Journal of Immunology 205 (1), 272-281, 2020 | 22 | 2020 |
| Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology NJ Hess, DP Turicek, J Riendeau, SJ McIlwain, E Contreras Guzman, ... Science Advances 9 (12), eadf0567, 2023 | 19 | 2023 |
| CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration KL Walker, SP Rinella, NJ Hess, DP Turicek, SA Kabakov, F Zhu, ... Leukemia & lymphoma 62 (5), 1167-1177, 2021 | 15 | 2021 |
| iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts NJ Hess, NS Bharadwaj, EA Bobeck, CE McDougal, S Ma, JD Sauer, ... Life Science Alliance 4 (7), 2021 | 10 | 2021 |
| Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment NJ Hess, JA Kink, P Hematti Frontiers in Immunology 14, 1143381, 2023 | 4 | 2023 |
| TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant AE Quamine, NR Mohrdieck, CA King, AA Griggs, JM Kline, MM Cho, ... bioRxiv, 2024.07. 09.602731, 2024 | 2 | 2024 |
| Griddient: a microfluidic array to generate reconfigurable gradients on-demand for spatial biology applications C Sanchez-de-Diego, M Virumbrales-Muñoz, B Hermes, TD Juang, ... Communications Biology 6 (1), 925, 2023 | 2 | 2023 |
| TLR10 (CD290) is a Regulator of Immune responses in human plasmacytoid dendritic cells P Deb, S Singh, E Kalyoussef, NJ Hess, RI Tapping, P Fitzgerald-Bocarsly The Journal of Immunology 213 (5), 577-587, 2024 | 1 | 2024 |
| Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression SP Rinella, HC Bell, NJ Hess, NM Hoang, TT Nguyen, DP Turicek, L Shi, ... bioRxiv, 2023.06. 07.544058, 2024 | 1 | 2024 |
| Combinatorial fedratinib and Venetoclax treatment is effective on human B cell acute lymphoblastic leukemia with high FLT3 expression SP Rinella, HC Bell, DP Turicek, L Shi, NM Hoang, L Rui, NJ Hess, ... bioRxiv, 2023.06. 07.544058, 2023 | 1 | 2023 |
| Interim analysis of T cell specific predictive biomarkers of graft-vs-host disease and relapse following post transplant cyclophosphamide prophylaxis NJ Hess, KV Nadiminti, P Hematti, CM Capitini 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | 1 | 2022 |
| 1107 Luminescent reporter assays for ADCP and ADCC characterization of immunotherapies targeting primary effector cells NJ Hess, JK Gilden, J Mitchell, D Garvin, R Moravec, P Stecha, F Fan, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury P Hematti, J Kink, C Capitini, M Forsberg, H Nicholas, Z Rosenkrans, ... US Patent App. 18/624,848, 2024 | | 2024 |
| Abstract A071: Pancreas organoid immune co-culture system identifies immunomodulators in pancreas adenocarcinoma JD Ebben, D Turicek, MS Hossan, A Stram, E Lin, N Hess, Z Mayhew, ... Molecular Cancer Therapeutics 22 (12_Supplement), A071-A071, 2023 | | 2023 |
| 382 TIM-3 blockade combined with adoptive therapy of ex vivo activated NK cells after allogeneic hematopoietic stem cell transplant reduces progression of relapsed murine … A Quamine, NR Mohrdieck, CA King, AA Griggs, KE Tippins, PD Bates, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
